Advances and opportunities in nanoimaging agents for the diagnosis of inflammatory lung diseases / Hema Brindha Masanam, Govindaraj Perumal, Saravanan Krishnan, Sachin Kumar Singh, Niraj Kumar Jha, Dinesh Kumar Chellappan, Kamal Dua, Piyush Kumar Gupta, Ashwin Kumar Narasimhan
The development of rapid, noninvasive diagnostics to detect lung diseases is a great need after the COVID-2019 outbreak. The nanotechnology-based approach has improved imaging and facilitates the early diagnosis of inflammatory lung diseases. The multifunctional properties of nanoprobes enable better spatial–temporal resolution and a high signal-to-noise ratio in imaging. Targeted nanoimaging agents have been used to bind specific tissues in inflammatory lungs for early-stage diagnosis. However, nanobased imaging approaches for inflammatory lung diseases are still in their infancy. This review provides a solution-focused approach to exploring medical imaging technologies and nanoprobes for the detection of inflammatory lung diseases. Prospects for the development of contrast agents for lung disease detection are also discussed. Graphical abstract.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
Erscheinungsort nicht ermittelbar: 2023 |
| Enthalten in: |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Masanam, Hema Brindha [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Contrast agents |
|---|
| Umfang: |
1 Online-Ressource (25 p) |
|---|
| doi: |
10.2217/nnm-2021-0427 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL01109608X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL01109608X | ||
| 003 | DE-627 | ||
| 005 | 20230713210643.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230609s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/nnm-2021-0427 |2 doi | |
| 035 | |a (DE-627)KFL01109608X | ||
| 035 | |a (KFL)prod_FICIBQ_10.2217/nnm-2021-0427 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Masanam, Hema Brindha |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Advances and opportunities in nanoimaging agents for the diagnosis of inflammatory lung diseases |c Hema Brindha Masanam, Govindaraj Perumal, Saravanan Krishnan, Sachin Kumar Singh, Niraj Kumar Jha, Dinesh Kumar Chellappan, Kamal Dua, Piyush Kumar Gupta, Ashwin Kumar Narasimhan |
| 264 | 1 | |a [Erscheinungsort nicht ermittelbar] |c 2023 | |
| 300 | |a 1 Online-Ressource (25 p) | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The development of rapid, noninvasive diagnostics to detect lung diseases is a great need after the COVID-2019 outbreak. The nanotechnology-based approach has improved imaging and facilitates the early diagnosis of inflammatory lung diseases. The multifunctional properties of nanoprobes enable better spatial–temporal resolution and a high signal-to-noise ratio in imaging. Targeted nanoimaging agents have been used to bind specific tissues in inflammatory lungs for early-stage diagnosis. However, nanobased imaging approaches for inflammatory lung diseases are still in their infancy. This review provides a solution-focused approach to exploring medical imaging technologies and nanoprobes for the detection of inflammatory lung diseases. Prospects for the development of contrast agents for lung disease detection are also discussed. Graphical abstract | ||
| 653 | |a contrast agents | ||
| 653 | |a imaging nanoparticles | ||
| 653 | |a inflammatory lungs diseases | ||
| 653 | |a medical imaging | ||
| 653 | |a respiratory diseases | ||
| 700 | 1 | |a Perumal, Govindaraj |e verfasserin |4 aut | |
| 700 | 1 | |a Krishnan, Saravanan |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Sachin Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Jha, Niraj Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Chellappan, Dinesh Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Dua, Kamal |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Piyush Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Narasimhan, Ashwin Kumar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nanomedicine |d London : Future Medicine Ltd, 2006 |h Online-Ressource |w (DE-627)KFL000006122 |w (DE-600)2254848-8 |w (DE-576)398100551 |x 1748-6963 |7 nnns |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/future-medicine-ejournals-pharmazie/doi.org/10.2217/nnm-2021-0427 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_FICIBQ_03 | ||
| 951 | |a AR | ||